The ECHELON-1 study compared the experimental brentuximab vedotin plus chemotherapy (A+AVD) to standard ABVD chemotherapy in patients with classical Hodgkin lymphoma. Dr Stephen Ansell (Mayo Clinic, Rochester, MN, USA) discusses the design and findings of the study as well as what was learned and how this will impact the treatment paradigm.
The abstract entitled ‘First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1’ (Abstract number 7503) was presented at the ASCO annual meeting, June 3-7, 2022.
1. Could you give us a brief overview of the ECHELON-1 study and its findings? (0:15)
2. What have we learned from the 6-year follow up data? (1:17)
3. Which patients are likely to benefit most from brentuximab vedotin plus chemotherapy, and in whom is it contraindicated? (2:44)
4. What will be the impact of these findings on the treatment paradigm for Hodgkin lymphoma? (4:38)
Disclosures: Stephen Ansell has received grant/research support from ADC Therapeutics, Affimed, BMS, Pfizer, Regeneron, SeaGen and Takeda and is on the advisory board for Affimed.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.
Share this Video
Related Videos In Lymphoma
William Townsend, EHA 2022: Final analysis of the GALLIUM study of obinutuzumab plus chemotherapy in follicular lymphoma
Dr William Townsend shares the latest data from the final analysis of the phase III GALLIUM study, which used the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab plus chemotherapy to follicular lymphoma. The study compared rituximab-based chemotherapy with obinutuzumab-based chemotherapy in patients with previously untreated advanced-stage follicular lymphoma. The abstract ‘OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM […]
PART TWO: Mazyar Shadman, EHA 2022: MB-106 for the treatment of relapsed/refractory follicular lymphoma: Results of the phase I/II study
In Part Two of this interview, Dr Mazyar Shadman (Fred Hutchinson Cancer Center, Seattle, Was, USA) presents the results of the follicular lymphoma cohort from his ongoing phase I/II clinical trial investigating MB-106 for B-cell lymphoma/CLL. He discusses the positive efficacy and safety data and the next steps in the clinical development of MB-106. Abstract […]
PART ONE: Mazyar Shadman, EHA 2022: MB-106 for the treatment of relapsed/refractory follicular lymphoma.
In part one of this interview, Dr Mazyar Shadman (Fred Hutchinson Cancer Center, Seattle, Was, USA) discusses the challenges of CAR-T therapy for follicular lymphoma and the advantages of MB-106, a third-generation, CD20-targeted, autologous CAR-T cell therapy over earlier generation CAR-T therapies. Abstract S207: ‘EFFICACY AND SAFETY OF A THIRD GENERATION CD20 CART (MB-106) FOR […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!